Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).
Bit Digital (NASDAQ:BTBT), a high-performance computing and digital asset mining company, has released its monthly treasury and staking update for March 2026, highlighting a significant Ethereum position and active yield-generation strategy.
Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.
Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.
Booz Allen Hamilton (NYSE:BAH) announced on April 7, 2026, the successful completion of its acquisition of Defy Security, a move aimed at consolidating its position as a dominant provider of high-speed, tech-enabled cybersecurity services for both commercial and government sectors.
Academy Sports + Outdoors (NASDAQ:ASO) issued a preliminary sales update for the first quarter of fiscal 2026 on April 7, 2026, signaling a robust start to the year ahead of its scheduled Analyst Day in Katy, Texas.
Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.
Anthropic has entered into a massive infrastructure agreement with Google (NASDAQ:GOOGL) and Broadcom (NASDAQ:AVGO) to secure approximately 3.5 gigawatts of computing capacity, marking one of the largest hardware commitments in the history of the artificial intelligence industry.
NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.
Aris Mining (NYSE:ARIS) reported record gold revenue of more than $360 million for the first quarter ended March 31, 2026, driven by rising production levels and an unprecedented surge in realized gold prices.
Artivion (NYSE:AORT), a leading cardiac and vascular surgery company, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the NEXUS™ Aortic Arch System.
Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.
-640x360.webp&w=3840&q=75)
